Bibliographic Details
Title: |
A microbead-enhanced electrochemical platform for β-amyloid peptide (1–42) detection |
Authors: |
Claudia do Amaral Razzino, Lívia Flório Sgobbi, Juliana Cancino-Bernardi, Angelica Maria Mazuera Zapata, Clara Cardoso Costa, Valtencir Zucolotto, Lucia Vieira, Anderson Oliveira Lobo |
Source: |
Frontiers in Sensors, Vol 5 (2024) |
Publisher Information: |
Frontiers Media S.A., 2024. |
Publication Year: |
2024 |
Collection: |
LCC:Biotechnology |
Subject Terms: |
screen-printed electrode, magnetic beads, amperometric immunosensor, amperometric sandwich immunoassay, β-amyloid peptide (1–42), Biotechnology, TP248.13-248.65 |
More Details: |
Alzheimer’s disease is the most prevalent form of dementia and is primarily characterized by the accumulation of β-amyloid and phosphorylated tau proteins in the brain, along with the degeneration of nerve cells, which leads to impairment of various cognitive functions. A significant biomarker of Alzheimer’s disease is the decreased level of soluble β-amyloid peptide (1–42) (Aβ1-42) in cerebrospinal fluid (CSF), as pathology progresses when CSF-Aβ1-42 levels drop below 192 pg mL−1. In this study, we developed an amperometric immunosensor based on magnetic beads as the platform for constructing the immunosensor. Monoclonal antibodies are immobilized on the MBs, enabling selective detection of Aβ1-42. The detection antibody is conjugated with the enzyme horseradish peroxidase, which, in the presence of H2O2 and hydroquinone, catalyzes the decomposition of H2O2 and the oxidation of hydroquinone to p-quinone, generating an electric current measured at a potential of −200 mV (vs. the Ag pseudo-reference electrode) using screen-printed carbon electrodes. The amperometric sandwich-type immunosensor demonstrates a linear response in the concentration range of 10 to 10,000 pg mL−1, with a detection limit of 7.4 pg mL−1, exhibiting excellent selectivity against the assessed interferents. These findings suggest the potential application of this immunosensor in the early diagnosis of Alzheimer’s disease, offering a sensitive and specific tool for clinical analysis. Despite its high performance, further studies are required to validate its robustness and applicability in complex clinical samples. |
Document Type: |
article |
File Description: |
electronic resource |
Language: |
English |
ISSN: |
2673-5067 |
Relation: |
https://www.frontiersin.org/articles/10.3389/fsens.2024.1508810/full; https://doaj.org/toc/2673-5067 |
DOI: |
10.3389/fsens.2024.1508810 |
Access URL: |
https://doaj.org/article/10496aea2ffd4f54ab271536c89d6c29 |
Accession Number: |
edsdoj.10496aea2ffd4f54ab271536c89d6c29 |
Database: |
Directory of Open Access Journals |